Infant Formula Safety Modernization Act of 2026

Bill Number

H.R. 7867

Origin Chamber

House

Congress

119th Congress, Session 2

Policy Area

Health

Status

Introduced

Latest Action

2026-03-09: Referred to the House Committee on Energy and Commerce.

Last Updated

2026-06-23T08:05:57Z

AI-Generated Summary

Purpose

The Infant Formula Safety Modernization Act of 2026 aims to improve the safety of infant formula by requiring standardized testing for harmful bacteria and microbes in both manufacturing facilities and finished products. It also mandates quick reporting of positive test results and inspection issues to federal regulators and Congress, building on existing food safety laws to prevent contamination risks for infants.

Key Provisions

• Updated Manufacturing Standards: Amends the Federal Food, Drug, and Cosmetic Act to require infant formula manufacturers to test for specific pathogens (harmful bacteria) and microorganisms, including Clostridium botulinum (a bacterium that causes botulism, a serious illness) and others designated by the FDA. Testing must cover:
• Manufacturing facilities, with recommended frequencies for environmental areas (defined as "Zone 2" for areas near but not touching the formula, and "Zone 3" for farther areas where contamination could spread via people, equipment, or air).
• Finished infant formula products, in addition to other required tests.
• Notification and Record-Keeping Requirements:
• Manufacturers must notify the FDA within one business day of any positive test result, even if the product hasn't left their control.
• Records of positive tests must be kept for FDA inspections.
• Inspection Standards: The FDA must create and enforce uniform inspection and compliance rules for all infant formula, including products from other countries.
• Congressional Reporting: The FDA must notify specific congressional committees (House and Senate Appropriations and relevant health/energy committees) within one business day of:
• Receiving a positive test notification from a manufacturer.
• Issuing an "official action indicated" classification (meaning serious issues found during an inspection requiring immediate response).
• Implementation Timeline: The FDA must issue final regulations within 90 days of the law's enactment.

Significant Changes to Existing Law

• Adds a new subsection (5) to Section 412(b) of the Federal Food, Drug, and Cosmetic Act, expanding "good manufacturing practices" (rules for safe production) to include mandatory pathogen testing and notifications—previously, these were not standardized or required for infant formula specifically.
• Introduces a new subsection (n) for congressional notifications, which did not exist before, increasing oversight beyond just the FDA.
• Updates references in the law to include these new testing rules, ensuring they integrate with current requirements for formula safety and quality control.

Potential Impacts

• On Government Agencies: The FDA will face increased responsibilities for developing test lists, issuing regulations quickly, conducting consistent inspections (including for imports), and reporting to Congress, potentially requiring more resources for monitoring and enforcement.
• On Citizens: Enhances protection for infants and families by reducing contamination risks in formula, a critical nutrition source for babies who cannot be breastfed. This could lead to fewer recalls or illnesses from pathogens.
• On International Relations: Applies uniform standards to imported infant formula, which may pressure foreign manufacturers to comply or face barriers, potentially affecting trade in baby products but promoting global safety norms without targeting specific countries.

Main Stakeholders Affected

• Infant Formula Manufacturers: Domestic and international companies must adopt new testing, record-keeping, and notification processes, increasing operational costs but ensuring safer products.
• FDA (Food and Drug Administration): Gains authority and duties to regulate testing, inspections, and reporting, acting as the primary enforcer.
• Congress: Specific committees receive timely updates on safety issues, enabling quicker legislative responses to problems.
• Consumers (Parents and Caregivers): Benefit indirectly through safer formula, with greater transparency on risks.
• Public Health Advocates and Infants: Positively impacted by reduced exposure to dangerous microbes, addressing vulnerabilities in a high-risk product.

Notable Legal, Constitutional, or Political Implications

• Legal: Strengthens enforcement under the Federal Food, Drug, and Cosmetic Act by mandating proactive testing and rapid notifications, potentially leading to more recalls or penalties for non-compliance. It promotes consistency in inspections, which could reduce legal challenges over uneven treatment of domestic vs. imported products.
• Constitutional: No direct conflicts; aligns with Congress's authority to regulate interstate commerce and food safety (under the Commerce Clause). The quick regulatory deadline ensures timely implementation without undue delegation of power to the FDA.
• Political: Increases bipartisan oversight through congressional notifications, fostering accountability in food safety amid past formula shortages and contamination events. It may spark debates on regulatory burdens for industry but emphasizes public health priorities without partisan framing in the bill text.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. DeLauro, Rosa L. [D-CT-3]

Cosponsors (27)

Rep. Grijalva, Adelita S. [D-AZ-7], Rep. Panetta, Jimmy [D-CA-19], Rep. Jacobs, Sara [D-CA-51], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Wilson, Frederica S. [D-FL-24], Rep. Bishop, Sanford D. [D-GA-2], Rep. Williams, Nikema [D-GA-5], Rep. Pappas, Chris [D-NH-1], Rep. Quigley, Mike [D-IL-5], Rep. Krishnamoorthi, Raja [D-IL-8], Rep. Schakowsky, Janice D. [D-IL-9], Rep. Tlaib, Rashida [D-MI-12], Rep. Thanedar, Shri [D-MI-13], Rep. Ross, Deborah K. [D-NC-2], Rep. Van Drew, Jefferson [R-NJ-2], Rep. Dean, Madeleine [D-PA-4], Rep. Cohen, Steve [D-TN-9], Rep. Meng, Grace [D-NY-6], Rep. Carson, André [D-IN-7], Rep. Magaziner, Seth [D-RI-2], Rep. Pressley, Ayanna [D-MA-7], Rep. Trahan, Lori [D-MA-3], Rep. Brownley, Julia [D-CA-26], Rep. Stansbury, Melanie A. [D-NM-1], Rep. García, Jesús G. "Chuy" [D-IL-4], Rep. Lawler, Michael [R-NY-17], Rep. Moulton, Seth [D-MA-6]

Recent Actions

• 2026-03-09: Referred to the House Committee on Energy and Commerce.
• 2026-03-09: Introduced in House
• 2026-03-09: Introduced in House

Bill Versions

• Infant Formula Safety Modernization Act of 2026 — issued 2026-03-09 — PDF (6 pages)